Pelthos Therapeutics Inc.

PTHS NYSE SEC CIK 1919246
Follow Pelthos Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $15.4M +107.9% vs same quarter last year
Net income −$7.9M +51.4% vs same quarter last year
EPS, diluted −$2.04 +61.5% vs same quarter last year
Operating cash flow −$5.2M +66.2% vs same quarter last year
Revenue by quarter
$0
$0
$7.4M
$9.4M
$10.9M
$15.6M
$15.4M
Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income5 fiscal years
−$60M−$40M−$20M$0FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$43.3M
FY24−$8M
FY23−$7.4M
FY22-
FY21-